新股消息 | 觅瑞集团更新招股书 核心产品已在新加坡成功商业化

Company Overview - Mirxes Holding Company Limited, founded in 2014 and headquartered in Singapore, specializes in microRNA (miRNA) technology for disease screening and diagnostic solutions in key Asian markets, including Singapore and China [5][6] - The company has one core product, GASTROClear™, and two other commercialized products, LUNGClear™ and Fortitude™, along with six candidates in preclinical stages [5] Product Details - GASTROClear™ is a blood-based miRNA test kit for gastric cancer screening, consisting of 12 miRNA biomarkers. It received regulatory approval from the Health Sciences Authority (HSA) in Singapore in May 2019 and has been successfully commercialized [5][6] - The company is one of the few globally to have regulatory approval for molecular cancer screening IVD products and is the first and only company to receive such approval for molecular gastric cancer screening [5] Market Position - Mirxes operates within the liquid biopsy subcategory of the overall disease screening market, focusing on non-invasive, affordable, and effective blood-based miRNA test kits for early cancer detection [6] - The company’s core product, GASTROClear™, is part of a growing trend in molecular diagnostics, utilizing liquid samples to detect cancer biomarkers [6] Financial Performance - The company reported revenues of approximately $17.76 million, $24.19 million, and $20.28 million for the years 2022, 2023, and 2024, respectively [6][7] - Gross profits for the same years were approximately $9.33 million, $13.58 million, and $8.89 million, indicating a gross margin of 52.5%, 56.2%, and 43.8% respectively [7]